Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb by Seini Moimoi | Sep 5, 2023 | Portfolio News
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline by Seini Moimoi | Aug 2, 2023 | Portfolio News
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Advance Clinical-Stage Bladder Cancer Pipeline by Seini Moimoi | Aug 2, 2023 | Uncategorized
Lexeo Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy by Seini Moimoi | Aug 1, 2023 | Portfolio News
CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC by Seini Moimoi | Jul 24, 2023 | Portfolio News
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) by Seini Moimoi | Jul 10, 2023 | Portfolio News
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine by Seini Moimoi | Jun 24, 2023 | Portfolio News
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress by Seini Moimoi | Jun 17, 2023 | Portfolio News
Avenge Bio Receives FDA Orphan Drug Designation for AVB-001 for the Treatment of Mesothelioma by Seini Moimoi | Jun 15, 2023 | Portfolio News
LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy by Seini Moimoi | Jun 13, 2023 | Uncategorized
